Search clinical trials for: TTI-622 PD-1 Inhibitor

Total 5136 results

Pfizer

Terminated

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Melanoma | Soft Tissue Sarcoma | Mycosis Fungoides | Breast Carcinoma | Solid Tumors | Squamous Cell Carcinoma | Human Papillomavirus-Related Malignant Neoplasm | Merkel-cell Carcinoma

United States
Pfizer

Active, not recruiting

A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies

Lymphoma | Multiple Myeloma

Japan
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China

Multiple Myeloma | Non-Hodgkin Lymphoma

China
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent Diffuse Large B-Cell... and other conditions

United States
Pfizer

Terminated

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Solid Tumor | Hematologic Malignancies

United States, Canada
Shanghai Chest Hospital

Recruiting

Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

Non Small Cell Lung Cancer

China
Memorial Sloan Kettering Cancer Center
Trillium Therapeutics Inc.

Active, not recruiting

A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma

Multiple Myeloma

United States
University Hospital, Bordeaux

Recruiting

Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors (SPICI)

Metastatic Renal Cell Carcinoma | Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score

France
Second Affiliated Hospital, School of Medicine,...

Recruiting

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Lung Cancer

China
Dong Wang

Not yet recruiting

TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer (TC)

ESCC

China
Sun Yat-sen University

Not yet recruiting

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Liver Diseases | Hepatocellular Carcinoma | Immunotherapy | Camrelizumab | Lenvatinib

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Single-center, Prospective Cohort Study of PD-1 Inhibitors on Clinical Outcomes of Carotid Plaques in Tumor Patients

Carotid Artery Plaque | Pd-1 Inhibitors

China
Adanate, Inc

Recruiting

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

Solid Tumor, Adult

United States
Istari Oncology, Inc.

Active, not recruiting

LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

Melanoma

United States
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

China
Sun Yat-sen University

Not yet recruiting

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

Liver Diseases | Hepatocellular Carcinoma | Immunotherapy | Sintilimab | Lenvatinib

China
Sun Yat-sen University
Second Affiliated Hospital of Guangzhou Medical University

Completed

HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

Carcinoma, Hepatocellular | Liver Neoplasms | Sintilimab | Portal Vein Tumor Thrombus

China
Calico Life Sciences LLC
AbbVie

Recruiting

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Advanced Solid Tumors Cancer

Korea, Republic of, Taiwan, Spain, United States, France, Japan, Israel
Canadian Cancer Trials Group
Melanoma and Skin Cancer Trials Limited

Recruiting

Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)

Unresectable/Metastatic Melanoma

Canada, Australia
Tongji Hospital
Wuhan University; Sun Yat-sen University; Wuhan Union Hospital, China

Suspended

Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors (IUNU-RC)

Non-clear Renal Cell Carcinoma

China
Second Affiliated Hospital, School of Medicine,...
Westlake Therapeutics

Recruiting

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Advanced Lung Cancer

China
Beijing Friendship Hospital

Recruiting

Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer

Locally Advanced Rectal Cancer

China
Peking University

Recruiting

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

Hepatocellular Carcinoma | Portal Vein Thrombosis

China
Pfizer

Recruiting

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (MagnetisMM-20)

Multiple Myeloma

United States, Israel
Shanghai Zhongshan Hospital

Recruiting

Gut Microbiota and Cancer Immunotherapy Response

Non-Small Cell Lung Cancer

China
Jason J. Luke, MD

Recruiting

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Melanoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumors | Cholangiocarcinoma | Bladder Cancer | Renal Cancer | Anal Cancer | Merkel Cell Carcinoma | HNSCC

United States
RWJ Barnabas Health at Jersey City Medical Center

Unknown

Tumor Grade Determines PD-1/PDL-1 Expression

Ovarian Cancer | Endometrial Cancer

United States
Pfizer
Incyte Corporation; MorphoSys AG

Recruiting

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

United States, Japan, Puerto Rico, Korea, Republic of
Zhongda Hospital

Recruiting

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC (CHANCE2202)

Hepatocellular Carcinoma

China
Second Affiliated Hospital of Soochow University
SciClone Pharmaceuticals

Recruiting

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Advanced Solid Tumor | Refractory Tumor

China
Zhongda Hospital

Recruiting

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC (CHANCE2201)

Hepatocellular Carcinoma

China
Li Xiao Wei

Not yet recruiting

HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL) (HAI-TL)

Hepatocellular Carcinoma With PVTT

China
Pain Therapeutics

Completed

Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma

Metastatic Melanoma

Israel
Chinese PLA General Hospital

Unknown

A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

Lymphoma | Solid Tumor

China
China Medical University, China

Recruiting

Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.

Metastatic Colorectal Adenocarcinoma | MSS | pMMR

China
Peking University

Not yet recruiting

Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ

Gastroesophageal Junction Cancer | Chemoradiotherapy | PD-1
Chinese PLA General Hospital

Unknown

Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs

Primary Mediastinal Large B-cell Lymphoma

China
SecuraBio

Terminated

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma

United States
Hunan Province Tumor Hospital

Completed

The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis

Lung Cancer

China
The First Affiliated Hospital of Guangdong Pharmaceutical...
University of Technology, Sydney; Guangzhou Anjie Biomedical Technology Co....

Unknown

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Non-small Cell Lung Cancer | Lung Neoplasm Malignant

China
University of Colorado, Denver
National Cancer Institute (NCI); Cancer League of Colorado

Withdrawn

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Colorectal Cancer | Microsatellite Instability High | Mismatch Repair Deficiency

United States
Tongji Hospital
National Natural Science Foundation of China

Recruiting

Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study (NICCE)

Esophageal Squamous Cell Carcinoma | Neoadjuvant Therapies

China
Centre Leon Berard
NETRIS Pharma

Recruiting

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies (IMMUNONET)

Advanced Solid Tumors | Metastatic Solid Tumors

France
Thomas Marron

Recruiting

Dupilumab_Metastatic NSCLC

Metastatic Non-small Cell Lung Cancer

United States
Fudan University

Recruiting

Local Therapy for Oligometastatic Esophageal Squamous Cell Cancer Patients Treated With PD-1 Inhibitor: a Prospective, Randomized, Phase III Clinical Trial.

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease | Radiotherapy

China
Buzzard Pharmaceuticals
Baylor Research Institute

Recruiting

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

Solid Tumor, Adult

United States
Tongji University

Recruiting

A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

NSCLC, Stage IIIA | EGF-R Negative Non-Small Cell Lung Cancer | ALK Negative NSCLC

China
Sinocelltech Ltd.

Unknown

Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
Instituto Nacional de Cancerologia de Mexico

Unknown

Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients

Non-Small Cell Lung Cancer

Mexico

Search clinical trials for: TTI-622 PD-1 Inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations